Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rolando D Z Lyles"'
Publikováno v:
PLoS ONE, Vol 18, Iss 10, p e0287126 (2023)
Androgen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and
Externí odkaz:
https://doaj.org/article/dcf70f64566a4e93901e812ee8157e56
Autor:
Govindi J. Samaranayake, Clara I. Troccoli, Mai Huynh, Rolando D. Z. Lyles, Karen Kage, Andrew Win, Vishalakshi Lakshmanan, Deukwoo Kwon, Yuguang Ban, Steven Xi Chen, Enrique Rodriguez Zarco, Merce Jorda, Kerry L. Burnstein, Priyamvada Rai
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Identifying actionable components in castration–resistant prostate cancer (CRPC) is critical for the development of effective treatments. Here, the authors show that the inhibition of the redox-protective protein TRX1 decreases the growth of CRPC c
Externí odkaz:
https://doaj.org/article/d2ca0dbfe1e54bac82aeb4b72d117967
Autor:
Rolando D. Z. Lyles, Kerry L. Burnstein, Stephanie Peacock, Jonathan Weitz, Pablo S. Magani, Meghan A. Rice, Fiorella Magani, Maria J. Martinez, Ann M. Greene
Publikováno v:
Molecular Cancer Research. 15:1469-1480
Castration-resistant prostate cancer (CRPC) progresses rapidly and is incurable. Constitutively active androgen receptor splice variants (AR-Vs) represent a well-established mechanism of therapeutic resistance and disease progression. These variants
Autor:
Clara I. Troccoli, Andrew Win, Kerry L. Burnstein, Rolando D. Z. Lyles, Merce Jorda, Priyamvada Rai, Steven Xi Chen, Vishalakshi Lakshmanan, Karen Kage, Mai Huynh, Govindi J. Samaranayake, Enrique Rodriguez Zarco, Deukwoo Kwon, Yuguang Ban
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature Communications
Androgen deprivation (AD) therapy failure leads to terminal and incurable castration-resistant prostate cancer (CRPC). We show that the redox-protective protein thioredoxin-1 (TRX1) increases with prostate cancer progression and in androgen-deprived
Autor:
Nikita S. Sharma, Yuguang Ban, Clara I. Troccoli, Priyamvada Rai, Rolando D. Z. Lyles, Govindi J. Samaranayake, Deukwoo Kwon, Steven Xi Chen, Mai Huynh, Kerry L. Burnstein, Sulagna Banerjee, Merce Jorda
Publikováno v:
Free Radical Biology and Medicine. 128:S75
Castration-resistant prostate cancer (CRPC) arises from a failure of standard-of-care androgen deprivation (AD) therapy to suppress emergence of castration-resistant variants from the original AD-responsive prostate cancer (ADPC). Identification of m
Autor:
Mai Q. Huynh, Priyamvada Rai, Deukwoo Kwon, Govindi J. Samaranayake, Yuguang Ban, Kerry L. Burnstein, Merce Jorda, Clara I. Troccoli, Rolando D. Z. Lyles, Steven Xi Chen
Publikováno v:
Cancer Research. 78:B032-B032
Androgen deprivation therapy (ADT) initially suppresses prostate cancer (PC) progression. However, castration-resistant PC (CRPC) cells inevitably emerge, resulting in incurable disease. We recently demonstrated that AD produces a form of cellular se